NASDAQ:OBSV
Delisted
ObsEva SA Stock News
$0.102
+0 (+0%)
At Close: Jun 21, 2023
Hot Penny Stocks For Your Buy List in September? 3 to Watch
06:00am, Tuesday, 30'th Aug 2022
Here's what you need to know about trading penny stocks on August 30th The post Hot Penny Stocks For Your Buy List in September? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Inf
ObsEva Receives Nasdaq Non-Compliance Notice
05:00am, Monday, 22'nd Aug 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva Files Second Quarter 2022 Financial Statements
08:01pm, Wednesday, 17'th Aug 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Why Is CarLotz Higher By More Than 30%: Here Are 28 Stocks Moving Premarket
10:08am, Wednesday, 10'th Aug 2022 Benzinga
Gainers
ObsEva SA (NASDAQ: OBSV) shares rose 33.8% to $0.4080 in pre-market trading. ObsEva recently announced a $31 million debt retirement and $11 million debt refinancing.
Aeglea BioTherapeutics,
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
04:00pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
01:32pm, Wednesday, 03'rd Aug 2022
ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
11:00am, Monday, 01'st Aug 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Why Is ObsEva (OBSV) Stock Down 70% Today?
11:45am, Wednesday, 27'th Jul 2022
Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press release early this morning.
ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress
01:53pm, Tuesday, 05'th Jul 2022
Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fi
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids
12:20pm, Friday, 17'th Jun 2022
ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.
ObsEva SA (OBSV) CEO Brian O'Callaghan on Q1 2022 Results - Earnings Call Transcript
11:27am, Tuesday, 17'th May 2022
ObsEva SA (NASDAQ:OBSV ) Q1 2022 Results Conference Call May 17, 2022 8:00 AM ET Company Participants Katja Buhrer - Chief Strategy Officer Brian O'Callaghan - Chief Executive Officer Brandi Howard -
7 Penny Stocks With 10x Potential This Year
07:00am, Tuesday, 17'th May 2022
These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
01:00am, Monday, 16'th May 2022
GENEVA, Switzerland May 1 6 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Company
What Are the Top 7 Penny Stocks? And Should You Buy?
06:42am, Thursday, 12'th May 2022
Penny stocks carry considerable risk, but they can also generate life-changing returns. Here are some to consider buying today.
ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
01:00am, Thursday, 12'th May 2022
GENEVA, Switzerland – May 1 2 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it p
